Editorial Annals of oncology : official journal of the European Society for Medical Oncology. 2025 Apr 5:S0923-7534(25)00133-4. doi: 10.1016/j.annonc.2025.03.022 Q156.72024

Neoadjuvant treatment of HER2-positive breast cancer: Has the era of antibody-drug conjugates arrived?

HER2阳性乳腺癌的新辅助治疗：抗体药物偶联物的时代来临了吗？ 翻译改进

作者单位 +展开

DOI: 10.1016/j.annonc.2025.03.022 PMID: 40194621

摘要 中英对照阅读

Copyright © Annals of oncology : official journal of the European Society for Medical Oncology. 中文内容为AI机器翻译，仅供参考！

相关内容

• Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer

  HER2阳性乳腺癌抗体药物偶联物治疗的进展

  Yongchao Yu et al.

  Breast cancer (Dove Medical Press). 2022 Dec 9:14:417-432.

• Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

  抗体-药物偶联物（ADC）在HER2阳性乳腺癌中的应用：现状与未来方向

  Emanuela Ferraro

  Breast cancer research : BCR. 2021 Aug 11;23(1):84.

• Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer

  临床综述：抗体-药物偶联物治疗HER2阳性乳腺癌

  Zohreh Najminejad et al.

  Molecular therapy : the journal of the American Society of Gene Therapy. 2023 Jul 5;31(7):1874-1903.

• Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer

  用于治疗HER2阳性乳腺癌的抗体偶联药物

  Mariana K Najjar et al.

  Genes. 2022 Nov 8;13(11):2065.

• Antibody-drug conjugates in HER2-positive breast cancer

  抗HER2阳性乳腺癌的抗体药物偶联物

  Lixi Li et al.

  Chinese medical journal. 2021 Dec 22;135(3):261-267.

• Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates

  圆桌讨论：抗体药物偶联物新时代下的HER2阳性晚期乳腺癌治疗策略

  Ying Yan

  Translational breast cancer research : a journal focusing on translational research in breast cancer. 2022 Apr 30:3:18.

• Antibody-drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here?

  抗体偶联药物治疗HER2阳性乳腺癌脑转移患者有效——未来研究展望

  S Sammons

  ESMO open. 2024 May;9(5):102990.

• The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

  新一代抗体药物偶联物的问世使HER2阳性乳腺癌治疗观念发生变化

  Santiago Escrivá-de-Romaní

  Cancer drug resistance (Alhambra, Calif.). 2023 Jan 12;6(1):45-58.